CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
AGN-210669 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01291108
NCT01291108Phase 2Completed
CompareCT.gov

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Feb 8, 2011·Updated Nov 6, 2013

In Brief

A Phase 2 clinical trial evaluating AGN-210669, bimatoprost, and 1 other intervention for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 125 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 8, 2011
Enrollment StartApr 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.4 years ago

Interventions

AGN-210669drug

AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

bimatoprostdrug

bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

bimatoprost vehicledrug

bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.